<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483470</url>
  </required_header>
  <id_info>
    <org_study_id>HAF78</org_study_id>
    <nct_id>NCT00483470</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      As per request by the Heath Authorities, the present clinical study will assess the
      immunogenicity and safety
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine</measure>
    <time_frame>1 month post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine AVAXIM 80U</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AVAXIM 80U Pediatric vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine (HAVRIX 720)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

        Inclusion criteria to be checked at the screening visit (SC):

          1. Toddlers, children and adolescents:

             Sub-Group 1: from 12 months to 3 years of age on the day of inclusion

             Sub-Group 2: from 4 to 6 years of age on the day of inclusion

             Sub-Group 3: from 7 to 9 years of age on the day of inclusion

             Sub-Group 4: from 10 to 12 years of age on the day of inclusion

             Sub-Group 5: from 13 to 15 years of age on the day of inclusion

          2. Screening informed consent form signed by the parent(s) or other legal representative
             for all the subjects and by the adolescents (sub-group 5 only)

        Inclusion criteria to be checked at the inclusion visit (V01):

          1. Toddlers, children and adolescents:

             Sub-Group 1: from 12 months to 3 years of age on the day of inclusion

             Sub-Group 2: from 4 to 6 years of age on the day of inclusion

             Sub-Group 3: from 7 to 9 years of age on the day of inclusion

             Sub-Group 4: from 10 to 12 years of age on the day of inclusion

             Sub-Group 5: from 13 to 15 years of age on the day of inclusion

          2. Inclusion informed consent form signed by the parent(s) or other legal representative
             for all the subjects and by the adolescents (sub-group 5 only)

          3. Able to attend all scheduled visits and to comply with all trial procedures

          4. Subject anti-HAV seronegative (IgG) according to the screening results (assay
             performed with local kit)

          5. Subject HBsAg seronegative and ALT &lt;40 IU/l according to the screening results

        Exclusion Criteria :

        Exclusion criteria to be checked at the inclusion visit (V01):

          1. Participation in another clinical trial in the 4 weeks preceding trial vaccination

          2. Planned participation in another clinical trial during the present trial period

          3. Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term
             systemic corticosteroids therapy

          4. Systemic hypersensitivity to any of the vaccines components or history of a
             life-threatening reaction to the trial vaccines or a vaccine containing the same
             substances

          5. Chronic illness at a stage that could interfere with trial conduct or completion

          6. Blood or blood-derived products received in the past 3 months

          7. Any vaccination in the 4 weeks preceding the trial vaccination

          8. Any vaccination planned in the 4 weeks following the trial vaccination

          9. History of hepatitis A infection (confirmed either clinically or serologically )

         10. Previous vaccination against hepatitis A with the trial vaccine or another hepatitis A
             vaccine

         11. Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

         12. History of /current seizures

         13. Clinical or serological evidence of systemic illness including Hepatitis C and HIV

         14. Febrile (axillary temperature ≥ 37.1°C) or acute illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guilin City</city>
        <state>Guangxi</state>
        <zip>541001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yongfu Country</city>
        <state>Guangxi</state>
        <zip>541800</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

